Patterns of treatment switching and healthcare resource utilization differences among real-world Medicare patients with metastatic pancreatic ductal adenocarcinoma who received first-line FOLFIRINOX

被引：0
|
作者：
Dieguez, Gabriela
Hirsch, Jared
Cockrum, Paul
Bhatt, Prachi
Tomicki, Samantha
Kim, George P.
机构：
[1] Milliman Inc, New York, NY USA
[2] Ipsen Biopharmaceut Inc, Crowley, TX USA
[3] George Washington Univ, Washington, DC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16286
引用
收藏
页数：1
相关论文
共 50 条
  • [31] First-line gemcitabine plus nab-paclitaxel versus FOLFIRINOX for metastatic pancreatic cancer in a real-world population
    Hatashima, Alycia
    Arango, Matthew J.
    Reardon, Joshua
    Freeman, Tracelyn
    Williams, Terence
    McLaughlin, Eric M.
    Abushahin, Laith
    FUTURE ONCOLOGY, 2022, 18 (20) : 2521 - 2532
  • [32] Second-line (2L) treatment patterns and clinical outcomes among real-world (RW) patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with FOLFIRINOX (FFX) or gemcitabine plus nab-paclitaxel (GnP) in the first-line (1L)
    Paluri, Ravi Kumar
    Silver, Michelle
    Cockrum, Paul
    Dennen, Syvart
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [33] Real-world assessment of healthcare costs for patients with metastatic pancreatic cancer following first-line chemotherapy initiation.
    Bullock, Andrea J.
    Rowan, Christopher G.
    Hill, Nina
    Yeganegi, Homa
    Chiorean, E. Gabriela
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [34] REAL-WORLD 30-DAY READMISSION PATTERNS AMONG COMMERCIALLY INSURED PATIENTS WITH METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA (MPDAC)
    Kim, G. P.
    Surinach, A.
    Cockrum, P.
    VALUE IN HEALTH, 2022, 25 (07) : S310 - S311
  • [35] Comparing real-world evidence among patients with metastatic pancreatic ductal adenocarcinoma treated with liposomal irinotecan
    Koeller, Jim
    Surinach, Andy
    Arikian, Steven R.
    Zivkovic, Marko
    Janeczko, Patrick
    Cockrum, Paul
    Kim, George
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
  • [36] TREATMENT PATTERNS AND HEALTHCARE-RESOURCE UTILIZATION AMONG PATIENTS WITH ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA WHO RECEIVED PLATINUM AND FLUOROPYRIMIDINE TREATMENT AT FIRST LINE
    Jaffe, D.
    Boudoures, A.
    Gricar, J.
    VALUE IN HEALTH, 2022, 25 (01) : S264 - S264
  • [37] Real-world healthcare resource utilization and treatment switching patterns in multiple sclerosis patients in a large US health plan
    Sanchirico, M.
    Ma, I.
    Caldwell-Tarr, A.
    Hashemi, L.
    Mudumby, P.
    Dufour, R.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 807 - 807
  • [38] Real-world biomarker testing and first-line treatment patterns among locally advanced, unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma patients in the US.
    Wellen, Maria
    Luu, Tony
    Gleason, Michelle Kathleen
    Majer, Istvan Matyas
    Reading, Stephanie Rummans
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 348 - 348
  • [39] Real-world treatment patterns and healthcare resource utilization among migraine patients: a German claims database analysis
    Gaul, Charly
    Seidel, Karolin
    Heuck, Alexander
    Silaidos, Carmina
    Mrosowsky, Thora
    Eberhardt, Alice
    Fritz, Bjorn
    Jacob, Christian
    JOURNAL OF MEDICAL ECONOMICS, 2023, 26 (01) : 667 - 678
  • [40] Real-world neo-adjuvant with or without adjuvant treatment patterns among pancreatic ductal adenocarcinoma patients in the US
    Navaratnam, Prakash
    Chase, Monica
    Friedman, Howard Steven
    Joo, Seongjung
    Pishvaian, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345